DX600, a small peptide with 26 residues, is a potent, highly selective inhibitor of angiotensin converting enzyme 2 (ACE2). A range of NMR methods including TOCSY and ROESY yield an assignment of its proton spectrum in water and constraints on its conformation. Constrained molecular dynamics simulations of solvated DX600 show that the peptide's most abundant conformer adopts a predominantly random coil conformation. Constrained by the disulfide bond, its backbone defines an overhand knot with frayed ends. 1. Introduction Angiotensin converting enzyme (ACE), a dipeptidase, is a key component of the renin-angiotensin system that regulates blood pressure [1, 2]. It catalyzes the conversion of inactive angiotensin I to angiotensin II, a potent vasoconstrictor, and the hydrolysis of bradykinin, a vasodilator. Consequently the treatment of hypertension makes extensive use of potent, selective inhibitors of ACE such as captopril and trandolapril [3]. Given the medical importance of the inhibition of ACE, the drug-design community has produced several X-ray structures of ACE-inhibitor complexes [4] and NMR solution-phase structures of the free inhibitors [5, 6]. ACE2 is a closely related enzyme which exhibits considerable sequence and structural homology with ACE [7, 8]. Both are peptidases with zinc at the active center. However, there are differences. Whereas ACE is widely distributed in the body, ACE2 is found principally in the heart, kidney, and testis. It cleaves the terminal leucine residue from the decapeptide angiotensin I and does not play a major role in the control of blood pressure. Knockout studies with mice indicate that ACE2 affects cardiac function [9]. To date, no inhibitors of ACE2 have entered clinical practice [3]. However, inhibitors of ACE2 have been developed as tools for exploring and modulating its biological function [10, 11]. Huang et al. screened peptide libraries displayed on phage and identified six highly potent inhibitors of ACE2 which do not inhibit ACE [12]. DX600, the most potent in the set with (the reciprocal of the equilibrium constant for the binding of the inhibitor, e.g., DX600, to the enzyme) equal to 2.8?nM, has the sequence Gly1-Asp2-Tyr3-Ser4-His5-Cys6-Ser7-Pro8-Leu9-Arg10-Tyr11-Tyr12-Pro13-Trp14-Trp15-Lys16-Cys17-Thr18-Tyr19-Pro20-Asp21-Pro22-Glu23-Gly24-Gly25-Gly26. It is acetylated at the amino terminus and amidated at the carboxyl terminus and a disulfide bond links the two cysteine residues, Cys6 and Cys17. DX600’s properties as an inhibitor mark it as a candidate for an NMR study and its unusual composition
References
[1]
A. A. Patchett and E. H. Cordes, “The design and properties of N-carboxyalkyldipeptide inhibitors of angiotensin-converting enzyme,” Advances in Enzymology and Related Areas of Molecular Biology, vol. 57, pp. 1–84, 1985.
[2]
J. L. Stanton and R. L. Webb, “Endogenous vasoactive peptides,” in Burger’s Medicinal Chemistry & Drug Discovery, D. J. Abraham, Ed., vol. 3, chapter 4, John Wiley & Sons, New York, NY, USA, 6th edition, 2003.
R. Natesh, S. L. U. Schwager, H. R. Evans, E. D. Sturrock, and K. R. Acharya, “Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme,” Biochemistry, vol. 43, no. 27, pp. 8718–8724, 2004.
[5]
A. G. Tzakos, N. Naqvi, K. Comporozos et al., “The molecular basis for the selection of captopril cis and trans conformations by angiotensin I converting enzyme,” Bioorganic and Medicinal Chemistry Letters, vol. 16, no. 19, pp. 5084–5087, 2006.
[6]
Y. Sakamoto, T. Ishii, I. Oonishi, and T. Ohmoto, “Conformational analysis of Ramipril (HOE 498) in a solution by NMR,” Journal of Molecular Structure, vol. 245, no. 3-4, pp. 379–389, 1991.
[7]
S. R. Tipnis, N. M. Hooper, R. Hyde, E. Karran, G. Christie, and A. J. Turner, “A human homolog of angiotensin-converting enzyme: cloning and functional expression as a captopril-insensitive carboxypeptidase,” The Journal of Biological Chemistry, vol. 275, no. 43, pp. 33238–33243, 2000.
[8]
P. Towler, B. Staker, S. G. Prasad et al., “ACE2 X-Ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis,” The Journal of Biological Chemistry, vol. 279, no. 17, pp. 17996–18007, 2004.
[9]
M. A. Crackower, R. Sarao, G. Y. Oudit et al., “Angiotensin-converting enzyme 2 is an essential regulator of heart function,” Nature, vol. 417, no. 6891, pp. 822–828, 2002.
[10]
J. A. Hernández Prada, A. J. Ferreira, M. J. Katovich et al., “Structure-based identification of small-molecule angiotensin-converting enzyme 2 activators as novel hypertensive agents,” Hypertension, vol. 51, no. 5, pp. 1312–1317, 2008.
[11]
T. J. Parry, L. Sekut, C. A. Rosen, et al., “Methods and compositions for modulating ACE-2 activity,” U.S. Patent 6,9009,033, May 2005.
[12]
L. Huang, D. J. Sexton, K. Skogerson et al., “Novel peptide inhibitors of angiotensin-converting enzyme 2,” The Journal of Biological Chemistry, vol. 278, no. 18, pp. 15532–15540, 2003.
[13]
K. Wüthrich, NMR of Proteins and Nucleic Acids, John Wiley & Sons, New York, NY, USA, 1986.
[14]
R. K. Harris, E. D. Becker, S. M. Cabral De Menezes, R. Goodfellow, and P. Granger, “NMR nomenclature. Nuclear spin properties and conventions for chemical shifts,” Pure and Applied Chemistry, vol. 73, no. 11, pp. 1795–1818, 2001.
[15]
S. Berger and W. Braun, 200 and More NMR Experiments, Wiley-VCH, Weinheim, Germany, 1998.
[16]
T. L. Hwang and A. J. Shaka, “Cross relaxation without TOCSY: transverse rotating-frame overhauser effect spectroscopy,” Journal of the American Chemical Society, vol. 114, no. 8, pp. 3157–3159, 1992.
[17]
S. L. Gordon and K. Wüterich, “Transient proton-proton overhauser effects in horse ferrocytochrome,” Journal of the American Chemical Society, vol. 100, no. 22, pp. 7094–7096, 1978.
[18]
D. H. Wu, A. D. Chen, and C. S. Johnson, “An improved diffusion-ordered spectroscopy experiment incorporating bipolar-gradient pulses,” Journal of Magnetic Resonance, Series A, vol. 115, no. 2, pp. 260–264, 1995.
[19]
L. G. Longsworth, “The mutual diffusion of light and heavy water,” Journal of Physical Chemistry, vol. 64, no. 12, pp. 1914–1917, 1961.
[20]
W. E. Steinmetz, J. D. Sadowsky, J. S. Rice, J. J. Roberts, and Y. K. Bui, “Determination of the aqueous-phase structure of 6-O-methylerythromycin from NMR constraints,” Magnetic Resonance in Chemistry, vol. 39, no. 4, pp. 163–172, 2001.
[21]
W. E. Steinmetz, B. L. Shapiro, and J. J. Roberts, “The structure of erythromycin enol ether as a model for its activity as a motilide,” Journal of Medicinal Chemistry, vol. 45, no. 22, pp. 4899–4902, 2002.
[22]
W. E. Steinmetz, A. Sparrow, and M. Somsouk, “Determination of the three-dimensional, solution-phase structure of the macrolide antibiotic oxolide in CDCl and D2O from NMR constraints,” Magnetic Resonance in Chemistry, vol. 43, no. 1, pp. 16–20, 2005.
[23]
T. A. Halgren, “MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular-interaction energies and geometries,” Journal of Computational Chemistry, vol. 20, no. 7, pp. 730–748, 1999.
[24]
N. J. Baxter and M. P. Williamson, “Temperature dependence of 1H chemical shifts in proteins,” Journal of Biomolecular NMR, vol. 9, no. 4, pp. 359–369, 1997.
[25]
W. E. Steinmetz, T. I. Bianco, M. Zollinger, and D. Pesiri, “Characterization of the multiple forms of mast cell degranulating peptide by NMR spectroscopy,” Peptide Research, vol. 7, no. 2, pp. 77–82, 1994.
[26]
A. Carrington and A. G. McLachlan, Introduction to Magnetic Resonance, Harper, New York, NY, USA, 1967.